| rosiglitazone / Generic mfg. |
| Completed | 4 | 180 | | Group 1 LADA patients treated by Placebo 8mg per day ;Group 2 T2DM patients treated by Placebo 8mg per day ;Group 3 LADA patients treated by Rosiglitazone 8mg ;Group 3 LADA patients treated by Rosiglitazone 8mg | Diabetes Center of CSU; Taiji Group, Self-financing, drug supported by Taiji Group and Ganli Group | 1) Latent autoimmune diabetes of adults (LADA). 2) Type 2 diabetes (T2DM). | | | | |
ChiCTR-TRC-10000879: Comparison of glycaemic control and beta-cell function among newly diagnosed type 2 diabetic patients treated with exenatide, insulin or rosiglitazone: a multicentre randomized parallel-group trial |
|
|
| Completed | 4 | 414 | | Exenatide injection (Byetta) ;Premixed insulin analog (Humalog Mix 25) ;Pioglitazone (Ruitong) | The Third Affiliated Hospital of Sun Yat-Sen University; Peking University People's Hospital, Eli Lilly, 5010 Program of Sun Yat-Sen University, Ministry of Health | Type 2 diabetes | | | | |
ChiCTR-TRC-13003529: Clinical and metabolic effects of rosiglitazone and metformin in non-obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial |
|
|
| Completed | 4 | 200 | | metformin (500mg, tid, 6months) ;rosiglitazone 4mg, qd, 6months | West China Second University Hospital; Level of the institution：, self-funded | polycystic ovary syndrome | | | | |
ChiCTR-TRC-13003642: Clinical and metabolic effects of rosiglitazone plus metformin and metformin only or rosiglitazone only in obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial |
|
|
| Completed | 4 | 210 | | metformin (500mg, tid, 6months) ;Rosiglitazone (4mg,qd,6months) ;Rosiglitazone (4mg,qd,6months) and metformin (500mg, tid, 6months) | West China Second University Hospital; Level of the institution：, self-funded | polycystic ovary syndrome | | | | |
2005-004253-10: viite: EudraCT-numero 2005-004253-10 Tyypin 2 diabetesta sairastavien maksansiirtopotilaiden rasvamaksan hoito insuliiniherkistäjällä (rosiglitatsoni) |
|
|
| Ongoing | 4 | 10 | Europe | Avandia, Avandia, Avandia | Helena Isoniemi | Maksansiirtopotilaat, joilla on todettu vaikea rasvamaksa (maksan rasvapitoisuus yli 50%) ja joilla on tyypin 2 diabetes. | | | | |
2007-003152-10: Influence du traitement par glitazones sur les Phospholipases A2 et sur l\'effet des Lipoprotéines de haute densité (HDL) sur la réactivité artérielle, au cours du diabète de type 2 |
|
|
| Ongoing | 4 | 60 | Europe | PIOGLITAZONE, ROSIGLITAZONE, PIOGLITAZONE, ROSIGLITAZONE | CHU DIJON | Diabète de type 2 | | | | |
EPOC study, ChiCTR2300071168: A multicenter phase III clinical study on the effect of pre-operative supplementation of calcitriol and calcium in preventing hypocalcemia in patients undergoing total thyroidectomy and bilateral central compartment neck dissection |
|
|
| Not yet recruiting | 3 | 480 | | a short-term preoperative administration of calcitriol and calcium: Starting from 2 days before surgery (-2 days), 0.25ug of calcitriol (rosiglitazone), qd, po; Simultaneously calcium carbonate tablets (calcium carbonate D), 600mg, bid, po; Take it for 3 days (including -2 days, -1 days, and 0 days on the day of surgery. ;none | Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital, Self funded | hypocalcemia | | | | |
2006-003001-49: Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease |
|
|
| Ongoing | 2 | 200 | Europe | Rosiglitazon, 1360, Avandia, Avandia | Leiden University Medical Center | Chronic kidney disease | | | | |
NCT04114136: Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies |
|
|
| Recruiting | 2 | 72 | US | Nivolumab or Pembrolizumab (dependent upon approved indication), Opdivo (nivolumab) or Keytruda (pembrolizumab), Metformin, Glucophage, Glucophage XR, Fortamet, and Glumetza, Rosiglitazone, Avandia | Dan Zandberg | Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor | 04/32 | 04/32 | | |
ChiCTR-TRC-09000652: The effect of Orlistat and Rosiglitazone on insulin action in a grouop of Chinese patients affected by the metabolic syndrome -- a randomized, single-blinded and placebo controlled study |
|
|
| Completed | 1 | 75 | | Orlistat 1 year versus Rosiglitazone | n/a; Level of the institution：, RGC Grant | Gland and Hormone Related Diseases | | | | |
ChiCTR-CCC-09000406: The relationship between gene polymorphisms and type 2 diabetes susceptibility and anti-diabetic drug therapy efficacy |
|
|
| Completed | 1 | 1200 | | no ;treated with rosiglitazone or Repaglinide to control blood glucose according to the genotype | Xiangya Hospital of Central South University; National Natural Science Foundation of China, National Natural Science Foundation of China | type 2 diabetes | | | | |
ChiCTR-TRC-09000670: Clinical and Metabolic Effects of Rosiglitazone on Women with Polycystic Ovarian Syndrome |
|
|
| Completed | N/A | 70 | | Rosiglitazone 4mg B.D. (8mg per day) 12 months versus Placebo 1 tab B.D. | N/A; Level of the institution：, 1) Lee Hysan Foundation Research Grant and Endowment Fund Research Grant 2003/2004 (United College, CUHK) 2) RGC Research Grant Direct Allocation 2004 (CUHK) | Polycystic Ovarian Syndrome | | | | |
| Completed | N/A | 2832 | | Intensive control of blood glucose and pressure ;Intensive control of blood glucose, lipids and blood pressure ;intensive control of blood glucose (with rosiglitazone sodium single or combined treatment), lipids and blood pressure ;Intensive control of blood glucose, lipids and blood pressure, combined the treatment of compound Danshen Di Wan ;(IMT>1.3mm) intensive control of blood glucose, lipids and blood pressure ;control group (IMT<1.2mm), random treatment in outpatient department ;control group (IMT without limit), random treatment in outpatient department | Beijing Hospital of China Ministry of Health; Ministry of Science and Technology, the 11th five-year science and technology support project | type 2 diabetes | | | | |
ChiCTR-TRC-06000683: A Randomized, Double Blind, Placebo Controlled Trial on the Effect of Rosiglitazone in Reversion of Newly Diagnosed Type 2 Diabetes to Non-Diabetic Status |
|
|
| Completed | N/A | 80 | | Primary intervention: Rosiglitasone or Placebo for 52 weeks. Secondary intervention: Standard advice on lifestyle modification for 52 weeks versus placebo | Dr Francis C.C. Chow; Dr Wing Bun Chan Dr Wing Yee So Dr Ronald C.W. Ma Dr Risa Ozaki Dr C.S. Cockram Dr H.K. Pang Dr I.M. Wong, Chinese University of Hong Kong (investigator-initiated study) GlaxoSmithKline Limited | Diabetes Mellitus | | | | |
| Completed | N/A | 210 | RoW | Rosiglitazone, Avandia, Placebo, crushed powder placebo | Centro de Investigacao em Saude de Manhica, University Health Network, Toronto, Barcelona Institute for Global Health | Malaria | 03/20 | 12/21 | | |
ACTRN12606000200583: Effect of Rosiglitazone on Glucocorticoid-stimulated 11betaHSD-1 Activity in Skeletal Muscle |
|
|
| Not yet recruiting | N/A | 20 | | | Dr Warrick Inder, Glaxo Smith Kline | Type 2 diabetes | | | | |